Hormonal
In patients with Class 3 obesity and Type 2 Diabetes, switching to weight-neutral or weight-losing diabetes medications (SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors) during a multidisciplinary weight management program results in significantly greater weight loss compared to switching to weight-gaining medications (sulphonylureas, insulin).
If you have severe obesity (BMI 40+) and Type 2 Diabetes, ask your doctor about switching your diabetes medications to 'weight-neutral' or 'weight-losing' types (like SGLT-2 inhibitors or GLP-1 agonists) instead of older 'weight-gaining' ones (like insulin or sulphonylureas). In this program, patients who made this switch lost nearly 8% of their body weight in 6 months, compared to only 2.4% for those who switched to weight-gaining drugs. This change also helped reduce their overall diabetes medication load and improved blood sugar control.
T2DM patients who started on weigh-neutral/losing medications in the program lost more weight than those started on weight-gaining medications (7:7 ± 5:3% vs. 2:4 ± 3:8%, p = 0:015).
Why this rating
Observational cohort study with real-world data; lacks randomization for medication assignment but uses rigorous statistical controls and clear outcome measures.
Source
Class 3 Obesity in a Multidisciplinary Metabolic Weight Management Program: The Effect of Preexisting Type 2 Diabetes on 6-Month Weight Loss
David Medveczky et al. · Journal of Diabetes Research · 2020
DOI 10.1155/2020/9327910
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →